OS Therapies (OSTX) said Wednesday its phase 2 OST-HER2 trial of an experimental treatment for lung metastatic osteosarcoma showed statistically significant results for the primary goal of 12-month event-free survival.
The company said the interim data from the ongoing 3-year overall survival secondary endpoint showed a strong trend in favor of the company's therapy in patients at both the 1-year and 2-year time points.
It added that all patients who reached the 12-month event-free survival endpoint remained alive.
"We are preparing to engage with the U.S. FDA on an accelerated pathway for approval in this extremely challenging indication," Paul Romness, MHP, Chair & CEO of OS Therapies, said.
Shares of the company rose more than 60% in premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。